LC
FOLD

Longitude (Cayman)’s Amicus Therapeutics FOLD Stock Holding History

Longitude (Cayman)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$261K – 73
2022
Q3 		$261K Buy
+25,000
New +$279K 0.42% 47
2022
Q2 		– Sell
-74,000
Closed -$609K – 61
2022
Q1 		$701K Sell
74,000
-163,000
-69% -$1.53M 0.67% 31
2021
Q4 		$2.74M Sell
237,000
-48,000
-17% -$535K 1.46% 26
2021
Q3 		$2.72M Buy
285,000
+29,000
+11% +$297K 1.2% 27
2021
Q2 		$2.47M Buy
256,000
+26,000
+11% +$254K 1.17% 30
2021
Q1 		$2.27M Buy
230,000
+145,000
+171% +$2.24M 0.87% 39
2020
Q4 		$1.96M Buy
+85,000
New +$1.74M 0.94% 32

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Longitude (Cayman)'s FOLD Position: Q4 2022 in Review

Longitude (Cayman) sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 25,000 shares — an estimated $261K sold.

Longitude (Cayman) first reported a position in FOLD in Q4 2020 and held it in 7 quarters. The position peaked at $2.74M in Q4 2021. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

  • Longitude (Cayman) reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Longitude (Cayman) sold 25,000 Amicus Therapeutics shares in Q4 2022, an estimated $261K.
  • Longitude (Cayman) first reported a position in Amicus Therapeutics in Q4 2020 and held it in 7 quarters.
  • Longitude (Cayman)'s Amicus Therapeutics position peaked at $2.74M in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Longitude (Cayman)'s 13F filing for Q4 2022, filed 6 Feb 2023.